Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

View the 50 largest pharmaceutical companies in the world listings here

Gilead Sciences logo

Gilead Sciences

Rank: 13

2022 Rank: 15

Foster City, California, United States
www.gilead.com

2022 Revenues ($USD) : $27,281,000,000.00
2022 R&D spend : $4,977,000,000.00
2022 Number of Employees : 17,000
Fiscal Year End : 12/31/22
Leader : CEO Daniel O’Day

Gilead Sciences reported strong financial results for 2022, with full-year Biktarvy sales growing 20% YoY to $10.4 billion and base business growth of 8% YoY. The company's initial 2023 guidance anticipates a 4-6% growth in its base business. The recent approval of Sunlenca for heavily treatment-experienced adults with multidrug-resistant HIV infection in the U.S. and Europe marks a significant milestone for Gilead. Additionally, the company experienced impressive sales growth in oncology with Trodelvy and in cell therapy with Yescarta and Tecartus. Gilead continues to invest in its clinical programs and aims to extend its reach to more patients and challenging diseases in the coming years. —BB
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE